Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer
( Last Updated : February 11, 2021)
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.